Cstone Pharmaceuticals Co. Ltd. presented preclinical data of CS-2009, a trispecific antibody targeting PD-1, CTLA-4 and VEGF-A, for cancer immunotherapy.
Antelope Surgical Solutions Inc. has received commercial IND approval from the FDA for its novel prostate cancer technology, AS-1986NS. AS1986NS, a fluorescent and lutetium-175 bearing drug, will be evaluated in trials with the aim of addressing prostate cancer identification and surgical margin delineation.
Aurigene Oncology Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety via a linker acting as SMARCA2 and/or SMARCA4 degradation inducers reported to be useful for the treatment of cancer.
Beijing Double-Crane Runchuang Technology Co. Ltd. has disclosed protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Gain-of-function mutations and overexpression of the EZH2 gene lead to H3K27Me3 accumulation, which in turn initiates tumorigenesis and tumor progression, thus making it a promising target for therapy.
Activin receptor-like kinase 5 (ALK5) is a member of the transforming growth factor-β (TGF-β) family associated with tumor development and progression that impacts cancer immune response within the tumor microenvironment.
Researchers from Canwell Biotech Ltd. presented preclinical data for CAN-2109, a novel long-acting immunogenic cell death inducer being developed for the treatment of cancer.
The use of interleukin-2 (IL-2)-directed therapies has been associated with systemic toxicities, regulatory T cell (Treg) activation and limited efficacy so far. Researchers from Regeneron Pharmaceuticals Inc. have described REGN-10597 (PD1-IL2Ra-IL2), a programmed cell death protein 1 (PD-1)-targeted, receptor-masked IL-2 immunocytokine.
RSS
